Form 8-K Amphastar Pharmaceutical For: Mar 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at BMO Capital
March 13, 2019 6:36 AM EDTBMO Capital analyst Gary Nachman raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $21.00) while maintaining a Market Perform rating.
4Q18 results were good overall, although the quarter did benefit from a couple of one-timers (Enoxaparin and insulin API).Management... More